{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urologic+Diseases&page=37", "query": { "condition": "Urologic Diseases", "page": 37 }, "page_size": 10 }, "pagination": { "page": 37, "page_size": 10, "total_count": 7009, "total_pages": 701, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urologic+Diseases&page=38&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urologic+Diseases&page=36&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T22:28:11.999Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02787083", "title": "A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystitis, Interstitial" ], "interventions": [ { "name": "Mirabegron", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Philadelphia Urosurgical Associates", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "FEMALE", "summary": "18 Years to 95 Years · Female only" }, "enrollment_count": 9, "start_date": "2016-08", "completion_date": "2019-07-05", "has_results": true, "last_update_posted_date": "2019-12-03", "last_synced_at": "2026-10-17T22:28:11.999Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02787083" }, { "nct_id": "NCT02091141", "title": "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Solid Tumors", "Biliary Cancer", "Salivary Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 673, "start_date": "2014-04-14", "completion_date": "2023-05-24", "has_results": true, "last_update_posted_date": "2024-07-23", "last_synced_at": "2026-10-17T22:28:11.999Z", "location_count": 60, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Springdale, Arkansas + 47 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02091141" }, { "nct_id": "NCT02753751", "title": "Optimizing Electronic Alerts for Acute Kidney Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Kidney Injury" ], "interventions": [ { "name": "AKI Alert", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6030, "start_date": "2018-03-26", "completion_date": "2020-01-06", "has_results": true, "last_update_posted_date": "2022-02-10", "last_synced_at": "2026-10-17T22:28:11.999Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02753751" }, { "nct_id": "NCT05878951", "title": "Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Urinary Incontinence", "Overactive Bladder Syndrome", "Overactive Bladder", "Urologic Diseases" ], "interventions": [ { "name": "OnabotulinumtoxinA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "MALE", "summary": "18 Years to 89 Years · Male only" }, "enrollment_count": 66, "start_date": "2023-07-13", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-17T22:28:11.999Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05878951" }, { "nct_id": "NCT01570153", "title": "Biomonitoring and Cardiorenal Syndrome in Heart Failure(BIONICS-HF) Trial", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cardiorenal Syndrome", "Acute Decompensated Heart Failure" ], "interventions": [], "intervention_types": [], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2012-03", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2014-03-24", "last_synced_at": "2026-10-17T22:28:11.999Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01570153" }, { "nct_id": "NCT01342172", "title": "Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2011-03", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2019-04-23", "last_synced_at": "2026-10-17T22:28:11.999Z", "location_count": 3, "location_summary": "Bethesda, Maryland • New York, New York • Salt Lake City, Utah", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01342172" }, { "nct_id": "NCT04424641", "title": "A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumor(s)", "Prostate Cancer", "Esophageal Cancer", "Triple Negative Breast Cancer (TNBC)", "Squamous Cell Carcinoma of Head and Neck (SCCHN)", "Non-small Cell Lung Cancer (NSCLC)", "Bladder Cancer", "Uterine Cancer" ], "interventions": [ { "name": "GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2020-07-15", "completion_date": "2021-10-29", "has_results": true, "last_update_posted_date": "2023-07-25", "last_synced_at": "2026-10-17T22:28:11.999Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04424641" }, { "nct_id": "NCT02437422", "title": "Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Insufficiency, Chronic" ], "interventions": [ { "name": "SANGUINATE", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Prolong Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 5, "start_date": "2015-06-05", "completion_date": "2015-11-18", "has_results": false, "last_update_posted_date": "2018-05-23", "last_synced_at": "2026-10-17T22:28:11.999Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02437422" }, { "nct_id": "NCT01446029", "title": "Telemonitoring to Improve Outcomes of Patients With Chronic Kidney Disease (CKD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "Video Telemonitoring Device with Clinical Care Modules", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Minneapolis Veterans Affairs Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 601, "start_date": "2012-03", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2014-08-04", "last_synced_at": "2026-10-17T22:28:11.999Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01446029" }, { "nct_id": "NCT02681731", "title": "Impact of Neuromonitoring During Cardiac Procedures", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Delirium", "Stroke", "Acute Kidney Injury" ], "interventions": [], "intervention_types": [], "sponsor": "Medtronic - MITG", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 250000, "start_date": "2016-03", "completion_date": "2017-12-31", "has_results": false, "last_update_posted_date": "2018-03-15", "last_synced_at": "2026-10-17T22:28:11.999Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02681731" } ] }